Boston Scientific Corporation provided earnings guidance for the second quarter and full year of 2024. The company estimates net sales growth for the full year 2024, versus the prior year period, to be in range of approximately 11 to 13% on a reported basis, and 10% to 12% on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.43 to $1.48.

The company estimates net sales growth for the second quarter of 2024, versus the prior year period, to be in a range of approximately 10.5% to 12.5% on a reported basis, and approximately 10% to 12% on an organic basis. Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.35 to $0.37.